Professor Jean-Claude Tardif (Montreal Heart Institute Research Centre and Professor of Medicine, University of Montreal, Montreal, Quebec, Canada) discusses the aims, rationale and recently released results of the COMMANDER-HF trial.
Filmed at ESC 2018, Munich.
View more content here.
Speaker Disclosure: Professor Jean-Claude Tardif has the following disclosures in relation to this video interview: grants from Amarin, AstraZeneca, DalCor, Esperion, Ionis, Pfizer, Sanofi and Servier. Honoraria from DalCor, Pfizer, Sanofi, Servier. Minor equity interest in DalCor.
1. Please describe the key aims of the COMMANDER-HF trial of rivaroxaban? (0:08)
2. What do we already know about the efficacy and safety of rivaroxaban and what was the rationale behind the COMMANDER-HF trial? (1:05)
3. Which patient groups were eligible for inclusion in the COMMANDER-HF trial? (2:28)
4. What separates the COMMANDER-HF trial from previous trials of oral anticoagulants in heart failure? (3:01)
5. What were the lessons from the COMMANDER-HF trial? (3:39)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via open-access content in multimedia formats.
Share this Video
Related Videos In Heart Failure
Hugh Calkins, AF Symposium 2021: Atrial Fibrillation and HFrEF and HFpEF
We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about atrial fibrillation and heart failure with reduced and preserved ejection fraction. Questions: What is the prevalence of atrial fibrillation (AF) in patients with heart failure (HF) and reduced (HFrEF) and preserved (HFpEF) ejection fraction? (0.13) What is the impact of AF on […]
Joachim Ehrlich, ESC 2020 – Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation with Heart Failure
We caught up with Prof Joachim Ehrlich (Head of Cardiology and Electrophysiology, St Josefs-Hospital, Wiesbaden, Germany) on the recent studies in the use of pulmonary vein isolation in patients with atrial fibrillation and heart failure and the advantages of cryoballoon ablation compared with radiofrequency ablation. He also gave us an overview of their recent cohort […]
Vishal Luther and Eileen Porter, HRC 2019 – Heart Failure and Atrial Fibrillation
We spoke to Dr Vishal Luther (Hammersmith Hospital, London, UK) and patient Eileen Porter at the 2019 Heart Rhythm Congress (HRC) in Birmingham, UK, about heart failure, atrial fibrillation and the patient experience. Speaker’s Disclosures: Vishal Luther has nothing to declare in relation to this video interview. touchCARDIO.com is an independent information resource supporting physicians, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!